Tag: prostate cancer

1. Adjuvant radiotherapy was found to increase the risk of urinary incontinence and urethral strictures compared to salvage radiotherapy in patients with prostate cancer. 2. Adjuvant radiotherapy did not show any benefit in biochemical control or time to hormone therapy following radical prostatectomy, compared to salvage radiotherapy. Evidence Rating Level: 1...
1. Adjuvant radiotherapy was found to increase the risk of urinary incontinence and urethral strictures compared to salvage radiotherapy in patients with prostate cancer. 2. Adjuvant radiotherapy did not show any benefit in biochemical control or time to hormone therapy following radical prostatectomy, compared to salvage radiotherapy. Evidence Rating Level: 1...
1. There is no evidence that adjuvant radiotherapy improves survival compared with early salvage radiotherapy following radical prostatectomy with localized or locally advanced prostate cancer. 2. Pre-surgical PSA, Gleason score, seminal vesicle involvement and surgical margins did not influence the effect of adjuvant radiotherapy on event-free survival. Evidence Rating Level: 1...
1. Men diagnosed with localized prostate cancer have lower self-reported quality of life outcomes, particularly sexual function in those who underwent radical prostatectomy. 2. Mental well-being was similar between men without prostate cancer and men who underwent active surveillance/watchful waiting or low dose rate brachytherapy, as their primary treatment for...
Tranexamic Acid During Prehospital Transport in Patients at Risk for Hemorrhage After Injury: A Double-blind, Placebo-Controlled, Randomized Clinical Trial 1. In trauma patients at risk for hemorrhage, pre-hospital administration of tranexamic acid did not significantly improve 30-day mortality compared to a placebo. 2. 30-day mortality outcomes were higher in the treatment...
1. Enzalutamide along with androgen-deprivation therapy was shown to significantly increase median overall survival among men with non-metastatic, castration-resistant prostate cancer. 2. Adverse events for enzalutamide and androgen-deprivation therapy were shown to be consistent with the established safety profile of enzalutamide. Evidence Rating Level: 1 (Excellent) Study Rundown: Enzalutamide is an approved therapy for...
1. Relugolix was shown to significantly decrease testosterone levels for a sustained period of time in male patients with advanced prostate cancer. 2. The risk of cardiovascular adverse events with relugolix therapy was found to be significantly lower than with leuprolide therapy. Evidence Rating Level: 1 (Excellent) Study Rundown: Long-acting injectable luteinizing...
1. Enzalutamide along with androgen-deprivation therapy was shown to significantly increase median overall survival among men with non-metastatic, castration-resistant prostate cancer. 2. Adverse events for enzalutamide and androgen-deprivation therapy were shown to be consistent with the established safety profile of enzalutamide. Evidence Rating Level: 1 (Excellent) Study Rundown: Enzalutamide is an approved...
1. In this prospective cohort, MRI-targeted biopsies alone, underestimated the histologic grade of prostate cancer tumors. 2. The combination of MRI targeted biopsy and systematic biopsy led to greater detection of all prostate cancers, and the upgrade of tumors to grade 3 or higher on histopathological analysis, upon radical prostatectomy,...
1. In men with prostate cancer, functional outcomes following moderately hypofractionated radiation therapy are clinically equivalent to those following conventionally fractionated radiation therapy. Evidence Rating Level: 2 (Good) External-beam radiation therapy (RT) is a primary radical treatment option for men with localized or locally advanced prostate cancer. The conventionally fractionated RT regimen...